P Noel Barrett

Summary

Affiliation: Baxter Healthcare Corporation
Country: USA

Publications

  1. ncbi request reprint History of TBE vaccines
    P Noel Barrett
    Baxter BioScience, Uferstrasse 15, A 2304 Orth Donau, Austria
    Vaccine 21:S41-9. 2003
  2. ncbi request reprint A clinical trial of a whole-virus H5N1 vaccine derived from cell culture
    Hartmut J Ehrlich
    Department of Global Research and Development, Baxter BioScience, Vienna, Austria
    N Engl J Med 358:2573-84. 2008
  3. ncbi request reprint Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines
    M Keith Howard
    Baxter AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    Biol Chem 389:569-77. 2008
  4. ncbi request reprint Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine
    Eva Maria Pöllabauer
    Global R and D, Baxter BioScience, Vienna, Austria
    Vaccine 28:4558-65. 2010
  5. doi request reprint A new approach to a Lyme disease vaccine
    Ian Livey
    Baxter Innovations GmbH, Biomedical Research Center, Orth an der Donau, Austria
    Clin Infect Dis 52:s266-70. 2011
  6. pmc A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models
    Otfried Kistner
    Global Research and Development, Baxter BioScience, Vienna, Austria
    PLoS ONE 5:e9349. 2010
  7. pmc A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals
    Hartmut J Ehrlich
    Global R and D, Baxter BioScience, Vienna, Austria
    Clin Infect Dis 54:946-54. 2012
  8. doi request reprint Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development
    P Noel Barrett
    Vaccine R and D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A 2304 Orth Donau, Austria
    Expert Rev Vaccines 12:395-413. 2013
  9. doi request reprint Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial
    P Noel Barrett
    Global Research and Development, Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Lancet 377:751-9. 2011
  10. doi request reprint Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines
    P Noel Barrett
    Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Expert Rev Vaccines 8:607-18. 2009

Collaborators

Detail Information

Publications43

  1. ncbi request reprint History of TBE vaccines
    P Noel Barrett
    Baxter BioScience, Uferstrasse 15, A 2304 Orth Donau, Austria
    Vaccine 21:S41-9. 2003
    ..This article describes the development and modification of these vaccines over this time frame, and illustrates the efficacy of the vaccine in preventing this severe CNS disease...
  2. ncbi request reprint A clinical trial of a whole-virus H5N1 vaccine derived from cell culture
    Hartmut J Ehrlich
    Department of Global Research and Development, Baxter BioScience, Vienna, Austria
    N Engl J Med 358:2573-84. 2008
    ..An urgent need exists for an H5N1 vaccine that is effective against divergent strains of H5N1 virus...
  3. ncbi request reprint Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines
    M Keith Howard
    Baxter AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    Biol Chem 389:569-77. 2008
    ..These data indicate that cell culture-grown, whole virus vaccines, based on the wild-type virus, allow the rapid high-yield production of a candidate pandemic vaccine...
  4. ncbi request reprint Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine
    Eva Maria Pöllabauer
    Global R and D, Baxter BioScience, Vienna, Austria
    Vaccine 28:4558-65. 2010
    ..4 microg formulation of FSME-IMMUN. We concluded that the FSME-IMMUN paediatric vaccine formulation is safe and highly immunogenic, not only for children <12 years, but also for adolescents <16 years...
  5. doi request reprint A new approach to a Lyme disease vaccine
    Ian Livey
    Baxter Innovations GmbH, Biomedical Research Center, Orth an der Donau, Austria
    Clin Infect Dis 52:s266-70. 2011
    ....
  6. pmc A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models
    Otfried Kistner
    Global Research and Development, Baxter BioScience, Vienna, Austria
    PLoS ONE 5:e9349. 2010
    ..These data supported the initiation of clinical studies with the same low doses of whole virus vaccine that had previously been demonstrated to be immunogenic in clinical studies with a whole virus H5N1 vaccine...
  7. pmc A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals
    Hartmut J Ehrlich
    Global R and D, Baxter BioScience, Vienna, Austria
    Clin Infect Dis 54:946-54. 2012
    ....
  8. doi request reprint Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development
    P Noel Barrett
    Vaccine R and D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A 2304 Orth Donau, Austria
    Expert Rev Vaccines 12:395-413. 2013
    ..These Vero cell-derived vaccines are licensed for prepandemic and pandemic use. The Vero platform is also being explored to develop next-generation live-attenuated and recombinant vaccines...
  9. doi request reprint Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial
    P Noel Barrett
    Global Research and Development, Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Lancet 377:751-9. 2011
    ..We investigated the safety, immunogenicity, and protective efficacy of a Vero-cell-culture-derived influenza vaccine, and assessed the correlation between vaccine efficacy and haemagglutination inhibition antibody titre...
  10. doi request reprint Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines
    P Noel Barrett
    Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Expert Rev Vaccines 8:607-18. 2009
    ..These developments have illustrated the value of this cell culture platform in the rapid development of vaccines against a range of virus diseases...
  11. ncbi request reprint Developing cell culture-derived pandemic vaccines
    P Noel Barrett
    Baxter BioScience, Global R and D, Biomedical Research Centre, Orth Donau, Austria
    Curr Opin Mol Ther 12:21-30. 2010
    ..Clinical data are provided from cell culture-derived vaccines that are at an advanced stage of development, and insights are provided into recent developments in the preclinical evaluation of more experimental technologies...
  12. pmc Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model
    Michael G Schwendinger
    Vaccine R and D, Baxter BioScience, Orth Donau, Austria
    PLoS ONE 8:e79022. 2013
    ..For clinical development of a novel multivalent OspA vaccine against Lyme borreliosis, serological assays are required which can be used to establish immune correlates of protection against infection with Borrelia...
  13. pmc A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations
    Annett Hessel
    R and D Vaccines, Biomedical Research Center, Baxter BioScience, Orth Donau, Austria
    PLoS ONE 5:e12217. 2010
    ..The aim of this study was to evaluate live vaccines which induce both strong humoral and cell-mediated immune responses against the novel human pandemic H1N1 influenza virus, and to show protection in a lethal animal challenge model...
  14. doi request reprint A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination
    Nicolas Sabarth
    Vaccine R and D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A 2304 Orth Donau, Austria
    Vaccine 30:5533-40. 2012
    ....
  15. ncbi request reprint Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming
    Maikel V W van der Velden
    Vaccine R and D, Baxter BioScience, Vienna, Austria
    Vaccine 30:6127-35. 2012
    ..The presented studies assessed different prime-boost regimens with a Vero cell-derived whole virus non-adjuvanted H5N1 vaccine...
  16. doi request reprint A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate
    Walter Wodal
    Vaccine R and D, Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Vaccine 30:4625-31. 2012
    ..The development of new vaccine manufacturing technologies is a cornerstone of influenza pandemic preparedness...
  17. doi request reprint Clinical development of a Vero cell culture-derived seasonal influenza vaccine
    Hartmut J Ehrlich
    Global R and D, Baxter BioScience, IZD Tower, Wagramerstraße 17 19, A 1220 Vienna, Austria
    Vaccine 30:4377-86. 2012
    ..We investigated the safety, immunogenicity and efficacy of a Vero cell culture-derived seasonal influenza vaccine and utilized these studies to establish a serological correlate of vaccine protection...
  18. pmc Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses
    Otfried Kistner
    Baxter AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    Vaccine 25:6028-36. 2007
    ..These data indicate that cell culture-grown whole virus vaccines, based on the wild-type virus, allow the rapid high yield production of a candidate pandemic vaccine...
  19. doi request reprint A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory
    Alexandra Loew-Baselli
    Global R and D, Baxter BioScience, Vienna, Austria
    Vaccine 30:5956-66. 2012
    ..ClinicalTrials.gov Identifier: NCT00976469...
  20. doi request reprint Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine
    Hartmut J Ehrlich
    Global R and D, Baxter BioScience, Vienna, Austria hartmut
    Vaccine 30:4543-51. 2012
    ..Immune responses to novel pandemic influenza vaccines may be influenced by previous exposure to antigenically similar seasonal strains...
  21. doi request reprint Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial
    Gerald Aichinger
    Global R and D, Baxter BioScience, IZD Tower, Wagramerstraße 17 19, A 1220 Vienna, Austria gerald
    Vaccine 29:9376-84. 2011
    ..Approximately 5000 cases of RRV disease, which is characterized by debilitating polyarthritis, are recorded each year in Australia. This study describes the first clinical trial of a candidate RRV vaccine...
  22. doi request reprint A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans
    Klaus K Orlinger
    Global Research and Development, Baxter BioScience, Vienna, Austria
    J Infect Dis 203:1556-64. 2011
    ....
  23. doi request reprint Chikungunya virus and the safety of plasma products
    Sandra M Leydold
    Global Pathogen Safety, Baxter BioScience, Vienna, Austria
    Transfusion 52:2122-30. 2012
    ..To verify the safety margins of plasma products with respect to CHIKV, commonly used virus inactivation steps were investigated for their effectiveness to inactivate this newly emerging virus...
  24. doi request reprint Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans
    Brian A Crowe
    Baxter BioScience, Biomedical Research Centre, Uferstr 15, A 2304 Orth an der Donau, Austria brian
    Vaccine 29:166-73. 2010
    ..Importantly, the inactivated whole virus H5N1 vaccine was just as effective in inducing CD4(+) T cell and memory B cell response in the elderly (60 years or over) as in the adult population (18-59 years)...
  25. doi request reprint Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial
    Nina Wressnigg
    Vaccine R and D, Baxter BioScience, Vienna, Austria
    Lancet Infect Dis 13:680-9. 2013
    ..We investigated the safety and immunogenicity of adjuvanted and non-adjuvanted vaccines containing protective epitopes from Borrelia species outer surface protein A (OspA) serotypes in healthy adults...
  26. pmc Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever
    Birgit Schäfer
    Department of Virology, Baxter BioScience, Biomedical Research Center, Orth Donau, Austria
    PLoS ONE 6:e24505. 2011
    ..Although, a good safety profile was historically attributed to the 17D vaccine, serious adverse events have been reported, making the development of a safer, more modern vaccine desirable...
  27. doi request reprint A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies
    Richard Fritz
    Baxter BioScience, Vaccine Research and Development, Orth an der Donau, Austria
    J Infect Dis 205:28-34. 2012
    ..After 2 immunizations, seroconversion rates based on antibody titers against HA and NA were similar, indicating the induction of equally strong immune responses against both proteins by this H5N1 vaccine...
  28. pmc H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model
    M Keith Howard
    Vaccine Research and Development, Baxter BioScience, Orth Donau, Austria
    PLoS ONE 6:e23791. 2011
    ..A lethal mouse model has been utilized which allows investigation of the protective efficacy of active vaccination or passive transfer of vaccine induced sera following lethal H5N1 challenge...
  29. pmc Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity
    Annett Hessel
    Department of Virology, Baxter BioScience, Biomedical Research Center, Orth Donau, Austria
    PLoS ONE 6:e16247. 2011
    ..The aim of this study was to evaluate the cross-protective potential of the hemagglutinins of five H5N1 strains of divergent clades using a live attenuated modified vaccinia Ankara (MVA) vector vaccine...
  30. doi request reprint Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model
    Nicolas Sabarth
    Baxter BioScience, Biomedical Research Centre, Uferstrasse 15, A 2304 Orth Donau, Austria
    Vaccine 28:650-6. 2010
    ..1, clade 2.2 and clade 2.3. Moreover, the results indicate that heterologous prime-boost immunization regimes might broaden the specificity of the anti-H5N1 antibody response...
  31. doi request reprint Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection
    Georg W Holzer
    Baxter BioScience, Biomedical Research Center, A 2304 Orth Donau, Austria
    Vaccine 29:4132-41. 2011
    ..Based on these findings, the inactivated RRV vaccine is expected to be efficacious and protect humans from RRV disease...
  32. ncbi request reprint A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses
    Martin Spruth
    Baxter Vaccines, Biomedical Research Centre, Uferstr 15, 2304 Orth Donau, Austria
    Vaccine 24:652-61. 2006
    ..Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre...
  33. pmc MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses
    Annett Hessel
    Vaccine R and D, Baxter BioScience, Orth Donau, Austria
    PLoS ONE 9:e88340. 2014
    ..We evaluated the ability of vectors based on modified vaccinia virus Ankara (MVA) expressing conserved influenza proteins to protect mice against lethal challenge with multiple influenza subtypes...
  34. ncbi request reprint Comparison of immunogenicity and safety between two paediatric TBE vaccines
    Eva Maria Pöllabauer
    Global R and D, Baxter BioScience, Industriestrasse 67, A 1220 Vienna, Austria
    Vaccine 28:4680-5. 2010
    ..01) and second (p<0.001) vaccination with Encepur Children than with FSME-IMMUN Junior, affecting half the children in the former group: 22.4% and 10.2% with FSME-IMMUN Junior vs. 49.0% and 51.0% for Encepur Children...
  35. doi request reprint Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme
    Alexandra Loew-Baselli
    Global R and D, Baxter BioScience, Wagramer Str 17 19, A 1221 Vienna, Austria
    Vaccine 29:7307-19. 2011
    ..This successful research programme demonstrated the strong immunogenicity and continued safety of the FSME-IMMUN vaccine, which is further confirmed by the performance reported under field conditions...
  36. pmc Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection
    Josef Mayrhofer
    Baxter BioScience, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    J Virol 83:5192-203. 2009
    ..Thus, the nonreplicating recombinant vaccinia virus vectors are promising vaccine candidates that induce a broad immune response and can be produced in an egg-independent and adjuvant-independent manner in a proven vector system...
  37. pmc Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice
    Christine Hohenadl
    Global Pathogen Safety, Baxter BioScience, Benatzkygasse 2 6, 1221 Vienna, Austria
    Virol J 11:70. 2014
    ..Convalescent plasma and fractionated immunoglobulins have been suggested as prophylactic or therapeutic interventions during an influenza pandemic...
  38. doi request reprint Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes
    Richard Fritz
    Baxter BioScience, Vaccine Research and Development, Biomedical Research Centre, Uferstrasse 15, A 2304 Orth a d Donau, Austria
    Vaccine 30:1165-9. 2012
    ..These data, therefore, fully support the use of TBE vaccines in geographic regions where virus subtypes heterologous to the vaccine strains are prevalent...
  39. pmc Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients
    Maikel V W van der Velden
    Vaccine R and D, Baxter BioScience, Vienna, Austria
    Clin Vaccine Immunol 21:867-76. 2014
    ..This study is registered at ClinicalTrials.gov under registration no. NCT00711295.). ..
  40. ncbi request reprint Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity
    Hartmut J Ehrlich
    Baxter BioScience, Global Clinical Research and Development, Industriestr 67, A 1221, Vienna, Austria
    Vaccine 22:217-23. 2003
    ..The results of both studies demonstrate that the FSME-IMMUN "new" vaccine is safe and highly immunogenic in adults...
  41. doi request reprint Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza
    Thomas R Kreil
    Global Pathogen Safety, Quality Product Support, Viral Vaccines, Manufacturing, Research and Development, and R and D Vaccines, Baxter BioScience, Vienna, Austria
    Transfusion 52:803-9. 2012
    ..Commercial-scale H-IVIG production from plasma collected from donors convalescent from or vaccinated against pandemic influenza A (H1N1) virus is described...
  42. pmc Quantitative detection of Borrelia burgdorferi sensu lato in erythema migrans skin lesions using internally controlled duplex real time PCR
    Maria O'Rourke
    Vaccine R and D, Baxter BioScience, Orth Donau, Austria
    PLoS ONE 8:e63968. 2013
    ..This is the first quantitative PCR study of human skin biopsies predominantly infected with B. afzelii and the first study to demonstrate a clear relationship between clinical symptoms in B. afzelii-infected patients and Borrelia burden...
  43. ncbi request reprint Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives
    Thomas R Kreil
    Global Pathogen Safety, Operations Central Europe, R and D Biopharmaceuticals, and R and D Vaccines, Baxter BioScience, Vienna, Austria
    Transfusion 46:1143-51. 2006
    ....